Last reviewed · How we verify
eltrombopag combining rituximab
Eltrombopag and rituximab together work to increase platelet production while depleting B cells to treat immune thrombocytopenia.
Eltrombopag and rituximab together work to increase platelet production while depleting B cells to treat immune thrombocytopenia. Used for Immune thrombocytopenia (ITP), refractory or relapsed.
At a glance
| Generic name | eltrombopag combining rituximab |
|---|---|
| Also known as | TPO-R agonist & anti-CD20 antibody |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Drug class | Combination therapy: thrombopoietin receptor agonist + monoclonal antibody |
| Target | TPO receptor (c-Mpl) and CD20 |
| Modality | Small molecule |
| Therapeutic area | Hematology/Immunology |
| Phase | FDA-approved |
Mechanism of action
Eltrombopag is a thrombopoietin receptor agonist that stimulates megakaryocyte maturation and platelet production. Rituximab is a CD20-targeting monoclonal antibody that depletes B cells, reducing autoimmune platelet destruction. The combination addresses both platelet supply and immune-mediated destruction in ITP.
Approved indications
- Immune thrombocytopenia (ITP), refractory or relapsed
Common side effects
- Thrombosis
- Infection
- Hepatotoxicity
- Infusion reactions
Key clinical trials
- TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) (PHASE4)
- Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: